Durability of transgene expression after rAAV gene therapy

Mol Ther. 2022 Apr 6;30(4):1364-1380. doi: 10.1016/j.ymthe.2022.03.004. Epub 2022 Mar 10.


Recombinant adeno-associated virus (rAAV) gene therapy has the potential to transform the lives of patients with certain genetic disorders by increasing or restoring function to affected tissues. Following the initial establishment of transgene expression, it is unknown how long the therapeutic effect will last, although animal and emerging human data show that expression can be maintained for more than 10 years. The durability of therapeutic response is key to long-term treatment success, especially since immune responses to rAAV vectors may prevent re-dosing with the same therapy. This review explores the non-immunological and immunological processes that may limit or improve durability and the strategies that can be used to increase the duration of the therapeutic effect.

Keywords: animals; gene expression; gene expression regulation; gene therapy; gene transfer techniques; genetic therapy/methods; genetic vectors; human genetics; transgenes.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dependovirus* / genetics
  • Gene Transfer Techniques
  • Genetic Therapy
  • Genetic Vectors* / genetics
  • Humans
  • Transgenes